

**DRUG UTILIZATION REVIEW BOARD**  
**January 20, 2021**  
**MO HealthNet**  
**VIA WEBEX ONLY**

**Committee Members Present:**

Susan Abdel-Rahman, PharmD, Chair  
Sandra Bollinger, PharmD  
Kenneth Haller, MD  
Charlene Heyde, RPH  
Rick Kegler  
Ginger Nicol, MD, CEDS  
Lisa Pierce, MD

**Committee Members Absent:**

Stacy Mangum, PharmD  
Jennifer Passanise, FNP

**MO HealthNet Staff Present:**

Joshua Moore, PharmD, Director of  
Pharmacy  
Mark Roaseau, R.Ph, Clinical Pharmacist  
Angela Wilson, Pharmacy Operations  
Manager  
Elizabeth Sissom, RN, Clinical  
Management  
Lisa E. Smith, Program Development  
Specialist  
Carmen Burton, Administrative Assistant  
Dr. Timothy Kling, MD, Acting Medical  
Director  
Elizabeth Short, Program Development  
Specialist  
Connie Sutter, Fiscal Manager

Jackie Hickman, Drug Rebate Unit  
Supervisor  
Olivia Rush, PharmD, Program Integrity  
Pharmacist

**Contractors in Attendance:**

Jennifer Colozza, PharmD, Conduent  
Megan Fast, PharmD, Conduent  
Luke Boehmer, PharmD, Conduent  
Janelle Sheen, PharmD, Conduent  
April Ash, PharmD, Conduent  
Katie Wilbers, PharmD, Conduent  
Geri Roling, Wipro  
Chelsea Pendleton, Wipro  
Valerie Schmitz, Wipro

**Others Attending:**

Adam Kopp  
Anna Parievsky  
Audrey Rattan  
Bill Eicholzer  
Bill Urbanek  
Brad Willie  
Brenda McLaughlin  
Brent Young  
Camille Kerr  
Christina Brandmeyer  
Dan Read  
Dana Pipkin

Dave Poskey  
Dawn B  
Frank Alvarado  
Holly Budlong  
James Baumann  
Jean Ritter  
Jeff Knappen  
Jessica Petrie  
Jill Eckenrod  
Joe Cirrincione  
John Schillo  
Kelly  
Laura Hill  
Leo Pratt  
Mark Kaiser  
Matthew T. Wright  
Melissa Basil  
Michele Shirley  
Patty Laster  
Rachelle Owens  
Rob Hansen  
Stephanie Kennedy  
Steve Isaki  
Susie Moroney  
Suzanne Morgan  
Taylor Alberson  
Terry McCurren  
Tina Rhinehart  
Tom Guyer  
WITTEK1

<p><b>Welcome, Introductions and Opening Remarks</b></p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself and facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p><b>Minutes Review</b></p>	<p><b>Discussion:</b> Minutes were reviewed from the October 2020 meeting – the footer was updated to the appropriate date.</p> <p><b>Decision:</b> The Board voted to accept these approved minutes with no additional revisions.</p>
<p><b>Pharmacy Program and Budget Update</b></p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> <li>- November 2020 Eligibles by Group</li> <li>- July – November 2020 Expenditures by Enrollment Group</li> <li>- July – November 2020 Expenditures by Service</li> <li>- FY21 Pharmacy Spend vs July – November 2020 Total Medicaid Spend</li> <li>- FY21 July – January 2021 Pharmacy Expenditures</li> <li>- Top 4 Drug Classes per Fiscal Year</li> <li>- July 2020 – January 2021 Rare Disease Expenditures</li> <li>- FY19 – FYTD2021 Rare Disease Expenditures</li> <li>- FY18 – FYTD21 Tamiflu Comparison</li> <li>- Show Me Strong Recovery Plan website (<a href="https://showmestrong.mo.gov/">https://showmestrong.mo.gov/</a>) <ul style="list-style-type: none"> <li>o COVID vaccine adverse reactions still need to be</li> </ul> </li> <li>- Dispensing Fee Changes – implementation coming 2.1.2021</li> <li>- Medicaid Expansion – implementation coming July 2021</li> <li>- 340B Enhancements</li> <li>- COVID Vaccine Billing and Reimbursement</li> <li>- Pharmacist as Other Licensed Professionals</li> <li>- Family Planning Enhancements</li> </ul>

<b>New Business</b>	
<b>New Drug Review</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> <li>o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action.</li> </ul> </li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<b>Clinical &amp; Fiscal Edits With No Annual Changes</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> <li>o 15 Day Supply – Oral Oncology Fiscal Edit</li> <li>o Acetaminophen Cumulative Dose Clinical Edit</li> <li>o BiDil Clinical Edit</li> <li>o Butalbital Combinations Excessive Therapy Edit <ul style="list-style-type: none"> <li>▪ Discussed \$1 million savings with recent changes to this edit</li> </ul> </li> <li>o Butalbital Combinations without Codeine Clinical Edit</li> <li>o Corlanor Clinical Edit</li> <li>o Entresto Clinical Edit</li> <li>o Selzentry Clinical Edit</li> </ul> </li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<b>15 Day Supply Fiscal Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Further detail was provided regarding how the edit functions.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions and added to the block vote.</p>

<p><b>Antipsychotics – 1<sup>st</sup> Generation (Typical) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Antipsychotics – 2<sup>nd</sup> Generation (Atypical) Clinical Edit and Reference List</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Reminder that MHD does reimburse pharmacists for the administration of long acting injectable agents.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Benzodiazepines (Select Oral) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- MHD is working on provider outreach to help inform the appropriate parties of the changes and new requirements.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Biosimilar vs Reference Products Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>CAR T-Cell Therapy Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center"><b>Diabetic Supply Quantity Limit Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Duchenne Muscular Dystrophy (DMD) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>High Cost Medication Kits Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>High Risk Therapies Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Isturisa Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p><b>Morphine Milligram Equivalent Accumulation Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Clarification was provided on which cancers are included in the exclusion criteria.</li> <li>- Discussion arose on what MME MHD would like to see as the final threshold – hoping to stay around 120 MME.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Non-Oral Contraceptives Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Opioids – Short-Acting Combinations Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Opioids – Short-Acting Single Agents Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center"><b>Out-of-State, Non-Bordering Pharmacies Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Psychotropic Medications Polypharmacy Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>PrEP Fiscal Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Spinal Muscular Atrophy (SMA) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- More details were asked in the experiments/investigational use of Spinraza or Evrysdi after Zolgensma <ul style="list-style-type: none"> <li>o Most states are not covering this as they are not required to cover investigational use</li> <li>o MO does not have any specific instances of this happening</li> <li>o Do we send these patients to the clinical trials? Yes</li> </ul> </li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p><b>Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Preferred Drug List Edits With No Annual Changes</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> <li>o Alzheimer’s Agents PDL Edit</li> <li>o Antiandrogenic Agents PDL Edit</li> <li>o Antiemetic 5-HT3, NK1 and Other Select Agents, Non-Injectable PDL Edit</li> <li>o Antiemetic, THC Derivatives PDL Edit</li> <li>o Anti-Parkinsonism MAO-B Inhibitor Agents PDL Edit</li> <li>o Hereditary Angioedema Agents PDL Edit</li> <li>o Opiate Emergency Reversal Agents PDL Edit</li> </ul> </li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Anticonvulsants, Dravet Syndrome PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Antiemetic 5HT3 and NK1 Agents, Injectables PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>



<p><b>Anti-Migraine Agents, Alternative Oral Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Clarification was provided on the criteria change for Ubrelyv due to its status change</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Antiretrovirals, Treatment Products Reference List</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p><b>Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Fibromyalgia Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Questions arose regarding the age limitations – it was explained that the agents are found in multiple edits and the lower age limitation matches the age found in the other edits</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>GI Motility Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Glucagon Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Neuropathic Pain Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center"><b>NSAID Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Questions arose on the need for pharmacies to call providers to switch between the prescription and OTC versions for diclofenac 1% gel.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Opiate Dependence Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Clarification was provided on the diagnoses codes for Naltrexone Tabs</li> <li>- Clarification was provided on the the Subxone waivers – does the state need to do anything? Referred to public announcement; possible changes to SPA for DMH</li> <li>- Discussed SUPPORT ACT stipulations</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Opioids, Long Acting PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Sedative Hypnotic Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center"><b>Skeletal Muscle Relaxants PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p><b>Somatostatic Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Tramadol-Like Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> </ul> <p><b>Decision:</b> The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p><b>Program Utilization Information – Conduent Update</b></p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Top 25 Drugs by Paid Amount 1st Quarter 2021 (July, August, September)</li> <li>- Top 25 Drugs by Paid Number 1st Quarter 2021 (July, August, September)</li> <li>- Call Center User Statistics November 2020</li> <li>- CyberAccess Logging Information</li> <li>- New Drug Statistics</li> </ul>

<p style="text-align: center;"><b>DUR Interventions – Conduent Update</b></p>	<p>Katie Wilbers with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Recent Interventions: <ul style="list-style-type: none"> <li>o Long-Term use of Opioids and Benzodiazepines</li> <li>o Post-Traumatic Stress Disorder</li> <li>o High-Risk Influenza</li> <li>o Anticonvulsant Drug Use Evaluation</li> </ul> </li> <li>- Potential RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Glucagon after visit for Hypoglycemia</li> </ul> </li> <li>- Outcomes: <ul style="list-style-type: none"> <li>o Will report Long-Term use of Opioids and Benzodiazepines in April</li> </ul> </li> </ul>
<p style="text-align: center;"><b>Closing</b></p>	<p>Lisa Pierce motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the <b>Drug Utilization Review Board</b> is scheduled via WebEx only on <b>Wednesday, April 21, 2021</b>.</p>

<b>Roll Call for January 20, 2021</b>				
	<b><u>Action Item</u></b>			
<b><u>Board Member</u></b>	<b>October Meeting Minutes</b>	<b>All Recommendations: Block Vote for CE, FE and PDL Edits</b>	<b>Closing</b>	<b>Adjournment</b>
<b>Susan Abdel-Rahman</b>	Y	Y	Y	Y
<b>Charlene Heyde</b>	Y	Y	Y	Y
<b>Sandra Bollinger</b>	SY	MY	Y	MY
<b>Kenneth Haller</b>	Y	Y	SY	Y
<b>Lisa Pierce</b>	MY	SY	MY	SY
<b>Jennifer Passanise</b>	A	A	A	A
<b>Stacy Mangum</b>	A	A	A	A
<b>Ginger Nicol</b>	Y	Y	Y	Y
<b>Rick Kegler</b>	Y	Y	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain